{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T08:04:37Z","timestamp":1792742677113,"version":"4.5.0"},"reference-count":68,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T00:00:00Z","timestamp":1777939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T00:00:00Z","timestamp":1777939200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AAPS PharmSciTech"],"DOI":"10.1208\/s12249-026-03434-2","type":"journal-article","created":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T20:10:04Z","timestamp":1778011804000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Understanding the Influence of Molarity, Buffer Capacity, and pH on Product-specific Guidance Dissolution Method for Developing a Discriminatory Dissolution Method for the Development of Mesalamine Products"],"prefix":"10.1208","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-0603-1492","authenticated-orcid":false,"given":"Ankit","family":"Kumar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sakshi","family":"Kunjir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-4148-171X","authenticated-orcid":false,"given":"Prakash Kumar","family":"Sirvi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-9362-8365","authenticated-orcid":false,"given":"Ayush","family":"Rohila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1834-7750","authenticated-orcid":false,"given":"Sadhana","family":"Dhyagala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1435-6115","authenticated-orcid":false,"given":"Rajkumar","family":"Malayandi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,5]]},"reference":[{"key":"3434_CR1","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.ijpharm.2008.05.012","volume":"364","author":"EL McConnell","year":"2008","unstructured":"McConnell EL, Fadda HM, Basit AW. Gut instincts: explorations in intestinal physiology and drug delivery. Int J Pharm. 2008;364:213\u201326. https:\/\/doi.org\/10.1016\/j.ijpharm.2008.05.012.","journal-title":"Int J Pharm"},{"key":"3434_CR2","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/j.jconrel.2024.04.047","volume":"370","author":"R Han","year":"2024","unstructured":"Han R, He H, Lu Y, Lu H, Shen S, Wu W. Oral targeted drug delivery to post-gastrointestinal sites. J Control Release. 2024;370:256\u201376. https:\/\/doi.org\/10.1016\/j.jconrel.2024.04.047.","journal-title":"J Control Release"},{"key":"3434_CR3","doi-asserted-by":"publisher","DOI":"10.3892\/br.2021.1472","volume":"15","author":"H Deissler","year":"2021","unstructured":"Deissler H, Krammer H, Gillessen A. pH\u2011dependent vs. constant release of mesalazine in the treatment of ulcerative colitis: do drug delivery concepts determine therapeutic efficacy? (review). Biomed Rep. 2021;15:96. https:\/\/doi.org\/10.3892\/br.2021.1472.","journal-title":"Biomed Rep"},{"key":"3434_CR4","doi-asserted-by":"publisher","first-page":"73","DOI":"10.2165\/00003495-198937010-00005","volume":"37","author":"G J\u00e4rnerot","year":"1989","unstructured":"J\u00e4rnerot G. Newer 5-aminosalicylic acid based drugs in chronic inflammatory bowel disease. Drugs. 1989;37:73\u201386. https:\/\/doi.org\/10.2165\/00003495-198937010-00005.","journal-title":"Drugs"},{"key":"3434_CR5","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.3109\/03639045.2011.560156","volume":"37","author":"T Bautzov\u00e1","year":"2011","unstructured":"Bautzov\u00e1 T, Rabi\u0161kov\u00e1 M, Lamprecht A. Multiparticulate systems containing 5-aminosalicylic acid for the treatment of inflammatory bowel disease. Drug Dev Ind Pharm. 2011;37:1100\u20139. https:\/\/doi.org\/10.3109\/03639045.2011.560156.","journal-title":"Drug Dev Ind Pharm"},{"key":"3434_CR6","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1007\/s12325-015-0206-4","volume":"32","author":"A Abinusawa","year":"2015","unstructured":"Abinusawa A, Tenjarla S. Release of 5-aminosalicylic acid (5-ASA) from mesalamine formulations at various pH levels. Adv Ther. 2015;32:477\u201384. https:\/\/doi.org\/10.1007\/s12325-015-0206-4.","journal-title":"Adv Ther"},{"key":"3434_CR7","doi-asserted-by":"publisher","DOI":"10.1186\/s12876-022-02474-9","volume":"22","author":"Y Ohtaki","year":"2022","unstructured":"Ohtaki Y, Uchiyama K, Kamiya H, Moriizumi E, Yamada M, Aoki Y, et al. The insoluble excretion of multi-matrix system mesalazine preparations in patients with ulcerative colitis. BMC Gastroenterol. 2022;22:390. https:\/\/doi.org\/10.1186\/s12876-022-02474-9.","journal-title":"BMC Gastroenterol"},{"key":"3434_CR8","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1590\/S2237-93632012000400011","volume":"32","author":"ICD Albuquerque","year":"2012","unstructured":"Albuquerque ICD, Carvalho MA, Batista RR, Formiga GJS. Bezoar by mesalazine tablets: cause of intestinal obstruction in Crohn\u2019s disease. J Coloproctol (Rio J). 2012;32:422\u20135. https:\/\/doi.org\/10.1590\/S2237-93632012000400011.","journal-title":"J Coloproctol (Rio J)"},{"key":"3434_CR9","doi-asserted-by":"publisher","DOI":"10.1093\/jscr\/rjy116","author":"SA Jain","year":"2018","unstructured":"Jain SA, Agarwal L, Khyalia A, Chandolia P, Kaknale H. Pharmacobezoar\u2014a rare case presented as gastric outlet obstruction. J Surg Case Rep. 2018. https:\/\/doi.org\/10.1093\/jscr\/rjy116.","journal-title":"J Surg Case Rep"},{"key":"3434_CR10","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1023\/B:DDAS.0000037825.23535.b1","volume":"49","author":"LP Piodi","year":"2004","unstructured":"Piodi LP, Ulivieri FM, Carini M, Piccoli A, Bardella MT. Case report: iatrogenic ileal obstruction in a patient with Crohn\u2019s disease. Dig Dis Sci. 2004;49:1287\u201390. https:\/\/doi.org\/10.1023\/B:DDAS.0000037825.23535.b1.","journal-title":"Dig Dis Sci"},{"key":"3434_CR11","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1136\/gut.48.4.571","volume":"48","author":"SG Nugent","year":"2001","unstructured":"Nugent SG. Intestinal luminal pH in inflammatory bowel disease: possible determinants and implications for therapy with aminosalicylates and other drugs. Gut. 2001;48:571\u20137. https:\/\/doi.org\/10.1136\/gut.48.4.571.","journal-title":"Gut"},{"key":"3434_CR12","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1007\/s13346-013-0185-4","volume":"4","author":"R Malayandi","year":"2014","unstructured":"Malayandi R, Kondamudi PK, Ruby PK, Aggarwal D. Biopharmaceutical considerations and characterizations in development of colon targeted dosage forms for inflammatory bowel disease. Drug Deliv Transl Res. 2014;4:187\u2013202. https:\/\/doi.org\/10.1007\/s13346-013-0185-4.","journal-title":"Drug Deliv Transl Res"},{"key":"3434_CR13","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1345\/aph.1K469","volume":"42","author":"PB Kale-Pradhan","year":"2008","unstructured":"Kale-Pradhan PB, Pradhan RS, Wilhelm SM. Multi-matrix system mesalamine: to use or not to use. Ann Pharmacother. 2008;42:265\u20139. https:\/\/doi.org\/10.1345\/aph.1K469.","journal-title":"Ann Pharmacother"},{"key":"3434_CR14","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1097\/MCG.0b013e3181595b56","volume":"42","author":"WJ Sandborn","year":"2008","unstructured":"Sandborn WJ. Oral 5-ASA therapy in ulcerative colitis: what are the implications of the new formulations? J Clin Gastroenterol. 2008;42:338\u201344. https:\/\/doi.org\/10.1097\/MCG.0b013e3181595b56.","journal-title":"J Clin Gastroenterol"},{"key":"3434_CR15","doi-asserted-by":"publisher","unstructured":"Efficacy of switching to pH-dependent release formulation of mesalazine at 3.6 g\/day from time-dependent release formulation of mesalazine at 4.0 g\/day in patients with Ulcerative Colitis. Journal of Crohn\u2019s and Colitis. 2015;9:S319\u201320. https:\/\/doi.org\/10.1093\/ecco-jcc\/jju027.598","DOI":"10.1093\/ecco-jcc\/jju027.598"},{"key":"3434_CR16","doi-asserted-by":"publisher","DOI":"10.2147\/CEG.S80237","author":"G Christophi","year":"2016","unstructured":"Christophi G, Rengarajan A, Ciorba M. Rectal budesonide and mesalamine formulations in active ulcerative proctosigmoiditis: efficacy, tolerance, and treatment approach. CEG. 2016. https:\/\/doi.org\/10.2147\/CEG.S80237.","journal-title":"CEG"},{"key":"3434_CR17","doi-asserted-by":"publisher","first-page":"2873","DOI":"10.1097\/MIB.0000000000000562","volume":"21","author":"M Boyle","year":"2015","unstructured":"Boyle M, Ting A, Cury DB, Nanda K, Cheifetz AS, Moss A. Adherence to rectal mesalamine in patients with ulcerative colitis: inflammatory bowel diseases. Inflamm Bowel Dis. 2015;21:2873\u20138. https:\/\/doi.org\/10.1097\/MIB.0000000000000562.","journal-title":"Inflamm Bowel Dis"},{"key":"3434_CR18","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/S0928-0987(01)00196-8","volume":"14","author":"SY Choe","year":"2001","unstructured":"Choe SY, Neudeck BL, Welage LS, Amidon GE, Barnett JL, Amidon GL. Novel method to assess gastric emptying in humans: the pellet gastric emptying test. Eur J Pharm Sci. 2001;14:347\u201353. https:\/\/doi.org\/10.1016\/S0928-0987(01)00196-8.","journal-title":"Eur J Pharm Sci"},{"key":"3434_CR19","doi-asserted-by":"publisher","first-page":"1680","DOI":"10.1016\/j.xphs.2018.02.016","volume":"107","author":"F Karkossa","year":"2018","unstructured":"Karkossa F, Klein S. A biopredictive in vitro comparison of oral locally acting mesalazine formulations by a novel dissolution model for assessing intraluminal drug release in individual subjects. J Pharm Sci. 2018;107:1680\u20139. https:\/\/doi.org\/10.1016\/j.xphs.2018.02.016.","journal-title":"J Pharm Sci"},{"key":"3434_CR20","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.ejps.2006.09.004","volume":"30","author":"RCA Schellekens","year":"2007","unstructured":"Schellekens RCA, Stuurman FE, Van Der Weert FHJ, Kosterink JGW, Frijlink HW. A novel dissolution method relevant to intestinal release behaviour and its application in the evaluation of modified release mesalazine products. Eur J Pharm Sci. 2007;30:15\u201320. https:\/\/doi.org\/10.1016\/j.ejps.2006.09.004.","journal-title":"Eur J Pharm Sci"},{"key":"3434_CR21","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.ijpharm.2015.02.051","volume":"484","author":"A Goyanes","year":"2015","unstructured":"Goyanes A, Hatton GB, Merchant HA, Basit AW. Gastrointestinal release behaviour of modified-release drug products: dynamic dissolution testing of mesalazine formulations. Int J Pharm. 2015;484:103\u20138. https:\/\/doi.org\/10.1016\/j.ijpharm.2015.02.051.","journal-title":"Int J Pharm"},{"key":"3434_CR22","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.ejpb.2015.09.002","volume":"97","author":"CJ Andreas","year":"2015","unstructured":"Andreas CJ, Chen Y-C, Markopoulos C, Reppas C, Dressman J. In vitro biorelevant models for evaluating modified release mesalamine products to forecast the effect of formulation and meal intake on drug release. Eur J Pharm Biopharm. 2015;97:39\u201350. https:\/\/doi.org\/10.1016\/j.ejpb.2015.09.002.","journal-title":"Eur J Pharm Biopharm"},{"key":"3434_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.jddst.2024.105844","volume":"98","author":"HM Fadda","year":"2024","unstructured":"Fadda HM. Effect of postprandial gastric conditions on in vitro drug release from modified release mesalamine formulations. J Drug Deliv Sci Technol. 2024;98:105844. https:\/\/doi.org\/10.1016\/j.jddst.2024.105844.","journal-title":"J Drug Deliv Sci Technol"},{"key":"3434_CR24","unstructured":"Masood Bhatti, Lorelei Lutter JH. The investigation of variability of the pharmacokinetics of mesalamine from various mesalamine formulations in randomized clinical trials. BioPharma Services Inc. Toronto, ONT, Canada. https:\/\/www.biopharmaservices.com\/wp-content\/uploads\/2021\/03\/Poster-15-CSPS-2011-Mesalamine-1.pdf"},{"key":"3434_CR25","doi-asserted-by":"publisher","first-page":"485","DOI":"10.5414\/CPP43485","volume":"43","author":"KK Midha","year":"2005","unstructured":"Midha KK, Rawson MJ, Hubbard JW. The bioequivalence of highly variable drugs and drug products. CP. 2005;43:485\u201398. https:\/\/doi.org\/10.5414\/CPP43485.","journal-title":"CP"},{"key":"3434_CR26","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1007\/s40268-015-0097-5","volume":"15","author":"S Tenjarla","year":"2015","unstructured":"Tenjarla S. Dissolution of commercially available mesalamine formulations at various pH levels. Drugs R D. 2015;15:211\u20135. https:\/\/doi.org\/10.1007\/s40268-015-0097-5.","journal-title":"Drugs R D"},{"key":"3434_CR27","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1021\/mp100198q","volume":"7","author":"HM Fadda","year":"2010","unstructured":"Fadda HM, Sousa T, Carlsson AS, Abrahamsson B, Williams JG, Kumar D, et al. Drug solubility in luminal fluids from different regions of the small and large intestine of humans. Mol Pharm. 2010;7:1527\u201332. https:\/\/doi.org\/10.1021\/mp100198q.","journal-title":"Mol Pharm"},{"key":"3434_CR28","doi-asserted-by":"publisher","first-page":"4281","DOI":"10.1021\/acs.molpharmaceut.7b00426","volume":"14","author":"B Hens","year":"2017","unstructured":"Hens B, Tsume Y, Bermejo M, Paixao P, Koenigsknecht MJ, Baker JR, et al. Low buffer capacity and alternating motility along the human gastrointestinal tract: implications for in vivo dissolution and absorption of ionizable drugs. Mol Pharm. 2017;14:4281\u201394. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.7b00426.","journal-title":"Mol Pharm"},{"key":"3434_CR29","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1016\/j.ejps.2013.09.020","volume":"51","author":"G Garbacz","year":"2014","unstructured":"Garbacz G, Ko\u0142odziej B, Koziolek M, Weitschies W, Klein S. A dynamic system for the simulation of fasting luminal pH-gradients using hydrogen carbonate buffers for dissolution testing of ionisable compounds. Eur J Pharm Sci. 2014;51:224\u201331. https:\/\/doi.org\/10.1016\/j.ejps.2013.09.020.","journal-title":"Eur J Pharm Sci"},{"key":"3434_CR30","doi-asserted-by":"publisher","first-page":"2343","DOI":"10.1002\/jps.22472","volume":"100","author":"C \u00c1lvarez","year":"2011","unstructured":"\u00c1lvarez C, N\u00fa\u00f1ez I, Torrado JJ, Gordon J, Potthast H, Garc\u00eda-Arieta A. Investigation on the possibility of biowaivers for ibuprofen. J Pharm Sci. 2011;100:2343\u20139. https:\/\/doi.org\/10.1002\/jps.22472.","journal-title":"J Pharm Sci"},{"key":"3434_CR31","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.ejpb.2019.03.012","volume":"139","author":"J Al-Gousous","year":"2019","unstructured":"Al-Gousous J, Ruan H, Blechar JA, Sun KX, Salehi N, Langguth P, et al. Mechanistic analysis and experimental verification of bicarbonate-controlled enteric coat dissolution: potential in vivo implications. Eur J Pharm Biopharm. 2019;139:47\u201358. https:\/\/doi.org\/10.1016\/j.ejpb.2019.03.012.","journal-title":"Eur J Pharm Biopharm"},{"key":"3434_CR32","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.ijpharm.2009.08.003","volume":"382","author":"HM Fadda","year":"2009","unstructured":"Fadda HM, Merchant HA, Arafat BT, Basit AW. Physiological bicarbonate buffers: stabilisation and use as dissolution media for modified release systems. Int J Pharm. 2009;382:56\u201360. https:\/\/doi.org\/10.1016\/j.ijpharm.2009.08.003.","journal-title":"Int J Pharm"},{"key":"3434_CR33","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.ejpb.2019.06.006","volume":"142","author":"D Amaral Silva","year":"2019","unstructured":"Amaral Silva D, Al-Gousous J, Davies NM, Bou Chacra N, Webster GK, Lipka E, et al. Simulated, biorelevant, clinically relevant or physiologically relevant dissolution media: the hidden role of bicarbonate buffer. Eur J Pharm Biopharm. 2019;142:8\u201319. https:\/\/doi.org\/10.1016\/j.ejpb.2019.06.006.","journal-title":"Eur J Pharm Biopharm"},{"key":"3434_CR34","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.ejpb.2016.03.024","volume":"103","author":"R Cristofoletti","year":"2016","unstructured":"Cristofoletti R, Dressman JB. Matching phosphate and maleate buffer systems for dissolution of weak acids: equivalence in terms of buffer capacity of bulk solution or surface pH? Eur J Pharm Biopharm. 2016;103:104\u20138. https:\/\/doi.org\/10.1016\/j.ejpb.2016.03.024.","journal-title":"Eur J Pharm Biopharm"},{"key":"3434_CR35","doi-asserted-by":"publisher","first-page":"2894","DOI":"10.1002\/jps.24460","volume":"104","author":"BJ Krieg","year":"2015","unstructured":"Krieg BJ, Taghavi SM, Amidon GL, Amidon GE. In vivo predictive dissolution: comparing the effect of bicarbonate and phosphate buffer on the dissolution of weak acids and weak bases. J Pharm Sci. 2015;104:2894\u2013904. https:\/\/doi.org\/10.1002\/jps.24460.","journal-title":"J Pharm Sci"},{"key":"3434_CR36","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1002\/bdd.1800","volume":"33","author":"Y Tsume","year":"2012","unstructured":"Tsume Y, Langguth P, Garcia\u2010Arieta A, Amidon GL. In silico prediction of drug dissolution and absorption with variation in intestinal pH for BCS class II weak acid drugs: ibuprofen and ketoprofen. Biopharm Drug Dispos. 2012;33:366\u201377. https:\/\/doi.org\/10.1002\/bdd.1800.","journal-title":"Biopharm Drug Dispos"},{"key":"3434_CR37","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1586\/ecp.12.2","volume":"5","author":"M Ham","year":"2012","unstructured":"Ham M, Moss AC. Mesalamine in the treatment and maintenance of remission of ulcerative colitis. Expert Rev Clin Pharmacol. 2012;5:113\u201323. https:\/\/doi.org\/10.1586\/ecp.12.2.","journal-title":"Expert Rev Clin Pharmacol"},{"key":"3434_CR38","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1007\/s12325-010-0087-5","volume":"28","author":"S Tenjarla","year":"2011","unstructured":"Tenjarla S, Abinusawa A. In-vitro characterization of 5-aminosalicylic acid release from MMX mesalamine tablets and determination of tablet coating thickness. Adv Ther. 2011;28:62\u201372. https:\/\/doi.org\/10.1007\/s12325-010-0087-5.","journal-title":"Adv Ther"},{"key":"3434_CR39","doi-asserted-by":"publisher","first-page":"9153","DOI":"10.1007\/s10973-025-14231-7","volume":"150","author":"S Sharma","year":"2025","unstructured":"Sharma S, Kunjir SA, Pathare PR, Deoriya J, Sahoo A, Malayandi R. Effect of solid-state characteristics and buffers on the solubility and dissolution behaviors of mesalamine. J Therm Anal Calorim. 2025;150:9153\u201369. https:\/\/doi.org\/10.1007\/s10973-025-14231-7.","journal-title":"J Therm Anal Calorim"},{"key":"3434_CR40","unstructured":"US FDA Product-Specific Guidances for Generic Drug Development database. https:\/\/www.accessdata.fda.gov\/scripts\/cder\/psg\/index.cfm?event=Home.Search#letterSearchBar"},{"key":"3434_CR41","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics14020291","volume":"14","author":"MA Garc\u00eda","year":"2022","unstructured":"Garc\u00eda MA, Varum F, Al-Gousous J, Hofmann M, Page S, Langguth P. In vitro methodologies for evaluating colon-targeted pharmaceutical products and industry perspectives for their applications. Pharmaceutics. 2022;14:291. https:\/\/doi.org\/10.3390\/pharmaceutics14020291.","journal-title":"Pharmaceutics"},{"key":"3434_CR42","doi-asserted-by":"publisher","first-page":"3870","DOI":"10.1021\/acs.molpharmaceut.0c00614","volume":"17","author":"N Salehi","year":"2020","unstructured":"Salehi N, Al-Gousous J, Mudie DM, Amidon GL, Ziff RM, Amidon GE. Hierarchical mass transfer analysis of drug particle dissolution, highlighting the hydrodynamics, pH, particle size, and buffer effects for the dissolution of ionizable and nonionizable drugs in a compendial dissolution vessel. Mol Pharm. 2020;17:3870\u201384. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.0c00614.","journal-title":"Mol Pharm"},{"key":"3434_CR43","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2023.122981","volume":"640","author":"HS Sardou","year":"2023","unstructured":"Sardou HS, Sadeghi F, Garekani HA, Akhgari A, Hossein Jafarian A, Abbaspour M, et al. Comparison of 5-ASA layered or matrix pellets coated with a combination of ethylcellulose and eudragits L and s in the treatment of ulcerative colitis in rats. Int J Pharm. 2023;640:122981. https:\/\/doi.org\/10.1016\/j.ijpharm.2023.122981.","journal-title":"Int J Pharm"},{"key":"3434_CR44","unstructured":"US FDA Draft Guidance on Mesalamine Tablet, delayed release 1.2 g [Internet]. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/psg\/PSG_022000.pdf"},{"key":"3434_CR45","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1016\/0016-5085(95)90691-6","volume":"108","author":"PH Layer","year":"1995","unstructured":"Layer PH, Goebell H, Keller J, Dignass A, Klotz U. Delivery and fate of oral mesalamine microgranules within the human small intestine. Gastroenterology. 1995;108:1427\u201333. https:\/\/doi.org\/10.1016\/0016-5085(95)90691-6.","journal-title":"Gastroenterology"},{"key":"3434_CR46","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1016\/S0016-5085(83)80017-1","volume":"85","author":"SN Rasmussen","year":"1983","unstructured":"Rasmussen SN, Binder V, Maier K, Bondesen S, Fischer C, Klotz U, et al. Treatment of Crohn\u2019s disease with peroral 5-aminosalicylic acid. Gastroenterology. 1983;85:1350\u20133.","journal-title":"Gastroenterology"},{"key":"3434_CR47","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1016\/S0016-5085(82)80075-9","volume":"83","author":"SN Rasmussen","year":"1982","unstructured":"Rasmussen SN, Bondesen S, Hvidberg EF, Hansen SH, Binder V, Halskov S, et al. 5-aminosalicylic acid in a slow-release preparation: bioavailability, plasma level, and excretion in humans. Gastroenterology. 1982;83:1062\u201370.","journal-title":"Gastroenterology"},{"key":"3434_CR48","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1002\/j.1552-4604.1993.tb05612.x","volume":"33","author":"JG Hardy","year":"1993","unstructured":"Hardy JG, Harvey WJ, Sparrow RA, Marshall GB, Steed KP, Macarios M, et al. Localization of drug release sites from an oral sustained\u2010release formulation of 5\u2010ASA (Pentasa\u00ae ) in the gastrointestinal tract using gamma scintigraphy. J Clin Pharmacol. 1993;33:712\u20138. https:\/\/doi.org\/10.1002\/j.1552-4604.1993.tb05612.x.","journal-title":"J Clin Pharmacol"},{"key":"3434_CR49","doi-asserted-by":"publisher","DOI":"10.1208\/s12248-020-0417-8","volume":"22","author":"DM Mudie","year":"2020","unstructured":"Mudie DM, Samiei N, Marshall DJ, Amidon GE, Bergstr\u00f6m CAS. Selection of in vivo predictive dissolution media using drug substance and physiological properties. AAPS J. 2020;22:34. https:\/\/doi.org\/10.1208\/s12248-020-0417-8.","journal-title":"AAPS J"},{"key":"3434_CR50","doi-asserted-by":"publisher","DOI":"10.1007\/s11095-019-2731-3","volume":"37","author":"C Litou","year":"2020","unstructured":"Litou C, Psachoulias D, Vertzoni M, Dressman J, Reppas C. Measuring pH and buffer capacity in fluids aspirated from the fasted upper gastrointestinal tract of healthy adults. Pharm Res. 2020;37:42. https:\/\/doi.org\/10.1007\/s11095-019-2731-3.","journal-title":"Pharm Res"},{"key":"3434_CR51","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1016\/S0021-9258(18)45087-9","volume":"142","author":"LC McGee","year":"1942","unstructured":"McGee LC, Hastings AB. The CARBON DIOXIDE TENSION AND ACID-BASE BALANCE OF JEJUNAL SECRETIONS IN MAN. J Biol Chem. 1942;142:893\u2013904. https:\/\/doi.org\/10.1016\/S0021-9258(18)45087-9.","journal-title":"J Biol Chem"},{"key":"3434_CR52","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/j.ijpharm.2019.02.019","volume":"560","author":"L Samuelsen","year":"2019","unstructured":"Samuelsen L, Holm R, Lathuile A, Sch\u00f6nbeck C. Buffer solutions in drug formulation and processing: how pKa values depend on temperature, pressure and ionic strength. Int J Pharm. 2019;560:357\u201364. https:\/\/doi.org\/10.1016\/j.ijpharm.2019.02.019.","journal-title":"Int J Pharm"},{"key":"3434_CR53","doi-asserted-by":"publisher","first-page":"38","DOI":"10.14227\/DT240317P38","volume":"24","author":"JW Mauger","year":"2017","unstructured":"Mauger JW. Physicochemical properties of buffers used in simulated biological fluids with potential application for in vitro dissolution testing: a mini-review. Dissolution Technol. 2017;24:38\u201351. https:\/\/doi.org\/10.14227\/DT240317P38.","journal-title":"Dissolution Technol"},{"key":"3434_CR54","doi-asserted-by":"publisher","first-page":"335","DOI":"10.3109\/02652049809006861","volume":"15","author":"G Weiss","year":"1998","unstructured":"Weiss G, Yamaguchi H, Ibuki R, Yasumura M, Ohnishi N. Microencapsulation of the renin inhibitor FK906 by phase separation of ethylcellulose in cyclohexane. J Microencapsul. 1998;15:335\u201346. https:\/\/doi.org\/10.3109\/02652049809006861.","journal-title":"J Microencapsul"},{"key":"3434_CR55","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1211\/0022357056172","volume":"57","author":"S Klein","year":"2005","unstructured":"Klein S, Stein J, Dressman J. Site-specific delivery of anti-inflammatory drugs in the gastrointestinal tract: an in-vitro release model. J Pharm Pharmacol. 2005;57:709\u201319. https:\/\/doi.org\/10.1211\/0022357056172.","journal-title":"J Pharm Pharmacol"},{"key":"3434_CR56","unstructured":"Australian Product Information-Pentasa \u00ae (Mesalazine) Prolonged Release Tablets And Granules."},{"key":"3434_CR57","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/S0939-6411(01)00134-5","volume":"51","author":"M Rudolph","year":"2001","unstructured":"Rudolph M. A new 5-aminosalicylic acid multi-unit dosage form for the therapy of ulcerative colitis. Eur J Pharm Biopharm. 2001;51:183\u201390. https:\/\/doi.org\/10.1016\/S0939-6411(01)00134-5.","journal-title":"Eur J Pharm Biopharm"},{"key":"3434_CR58","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1007\/BF01980047","volume":"12","author":"LML Stolk","year":"1990","unstructured":"Stolk LML, Rietbroek R, Wiltink EH, Tukker JJ. Dissolution profiles of mesalazine formulationsin vitro. Pharmaceutisch Weekblad Scientific Edition. 1990;12:200\u20134. https:\/\/doi.org\/10.1007\/BF01980047.","journal-title":"Pharmaceutisch Weekblad Scientific Edition"},{"key":"3434_CR59","doi-asserted-by":"publisher","first-page":"7","DOI":"10.14227\/DT150308P7","volume":"15","author":"MC Chuong","year":"2008","unstructured":"Chuong MC, Christensen JM, Ayres JW. New dissolution method for mesalamine tablets and capsules. Dissolution Technol. 2008;15:7\u201314. https:\/\/doi.org\/10.14227\/DT150308P7.","journal-title":"Dissolution Technol"},{"key":"3434_CR60","unstructured":"Jayesh Parmar*, Ph. D., Manish Rane, Ph. D., Viena Dias, M. Pharm., and Ali Rajabi-Siahboomi, Ph. D. Formulation of Extended Release Multiparticlate Systems using Ethylcellulose. Pharma Times [Internet]. 2010;42. https:\/\/www.researchgate.net\/publication\/280568926_Formulation_of_Extended_Release_Multiparticlate_Systems_using_Ethylcellulose?enrichId=rgreq-34a439a56ed3daca698dc42173e02060-XXX&enrichSource=Y292ZXJQYWdlOzI4MDU2ODkyNjtBUzoyNTY5NjQ2NTk3NzM0NDFAMTQzODI3NjU1Nzc5MQ%3D%3D&el=1_x_3&_esc=publicationCoverPdf"},{"key":"3434_CR61","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.rinphs.2011.12.001","volume":"2","author":"MN Al Ameri","year":"2012","unstructured":"Al Ameri MN, Nayuni N, Anil Kumar KG, Perrett D, Tucker A, Johnston A. The differences between the branded and generic medicines using solid dosage forms: in-vitro dissolution testing. Results in Pharma Sciences. 2012;2:1\u20138. https:\/\/doi.org\/10.1016\/j.rinphs.2011.12.001.","journal-title":"Results in Pharma Sciences"},{"key":"3434_CR62","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/0378-5173(93)90344-F","volume":"91","author":"M Ashford","year":"1993","unstructured":"Ashford M, Fell JT, Attwood D, Woodhead PJ. An in vitro investigation into the suitability of pH-dependent polymers for colonic targeting. Int J Pharm. 1993;91:241\u20135. https:\/\/doi.org\/10.1016\/0378-5173(93)90344-F.","journal-title":"Int J Pharm"},{"key":"3434_CR63","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1111\/j.1365-2125.1987.tb03061.x","volume":"23","author":"L Christensen","year":"1987","unstructured":"Christensen L, Slot O, Sanchez G, Boserup J, Rasmussen S, Bondesen S, et al. Release of 5\u2010aminosalicylic acid from Pentasa during normal and accelerated intestinal transit time. Br J Clin Pharmacol. 1987;23:365\u20139. https:\/\/doi.org\/10.1111\/j.1365-2125.1987.tb03061.x.","journal-title":"Br J Clin Pharmacol"},{"key":"3434_CR64","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.ijpharm.2014.04.019","volume":"468","author":"FJO Varum","year":"2014","unstructured":"Varum FJO, Merchant HA, Goyanes A, Assi P, Zboranov\u00e1 V, Basit AW. Accelerating the dissolution of enteric coatings in the upper small intestine: evolution of a novel pH 5.6 bicarbonate buffer system to assess drug release. Int J Pharm. 2014;468:172\u20137. https:\/\/doi.org\/10.1016\/j.ijpharm.2014.04.019.","journal-title":"Int J Pharm"},{"key":"3434_CR65","doi-asserted-by":"publisher","first-page":"10","DOI":"10.14227\/DT220315P10","volume":"22","author":"G Bredael","year":"2015","unstructured":"Bredael G, Liang S, Hahn D. A strategy for quality control dissolution method development for immediate-release solid oral dosage forms. Dissolution Technol. 2015;22:10\u20136. https:\/\/doi.org\/10.14227\/DT220315P10.","journal-title":"Dissolution Technol"},{"key":"3434_CR66","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1016\/j.ejps.2017.06.021","volume":"106","author":"S Cascone","year":"2017","unstructured":"Cascone S. Modeling and comparison of release profiles: effect of the dissolution method. Eur J Pharm Sci. 2017;106:352\u201361. https:\/\/doi.org\/10.1016\/j.ejps.2017.06.021.","journal-title":"Eur J Pharm Sci"},{"key":"3434_CR67","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/S0928-0987(01)00095-1","volume":"13","author":"P Costa","year":"2001","unstructured":"Costa P, Sousa Lobo JM. Modeling and comparison of dissolution profiles. Eur J Pharm Sci. 2001;13:123\u201333. https:\/\/doi.org\/10.1016\/S0928-0987(01)00095-1.","journal-title":"Eur J Pharm Sci"},{"key":"3434_CR68","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1016\/j.physa.2017.05.033","volume":"486","author":"M Ignacio","year":"2017","unstructured":"Ignacio M, Chubynsky MV, Slater GW. Interpreting the weibull fitting parameters for diffusion-controlled release data. Physica A Stat Mech Appl. 2017;486:486\u201396. https:\/\/doi.org\/10.1016\/j.physa.2017.05.033.","journal-title":"Physica A Stat Mech Appl"}],"container-title":["AAPS PharmSciTech"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12249-026-03434-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1208\/s12249-026-03434-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12249-026-03434-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T16:08:50Z","timestamp":1780502930000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1208\/s12249-026-03434-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,5]]},"references-count":68,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,5]]}},"alternative-id":["3434"],"URL":"https:\/\/doi.org\/10.1208\/s12249-026-03434-2","relation":{},"ISSN":["1530-9932"],"issn-type":[{"value":"1530-9932","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,5]]},"assertion":[{"value":"4 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not required.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"Authors declare no conflicts of interest\/competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"195"}}